Back to Search VC Home Page
Venture Capital Search Engine
search over 1,000 Venture Capital related sites
Keywords about VC:  

BioVentures Investors

1.Abingworth - Portfolio Companies   (100%):
Portfolio Companies Abingworth Bioventures IIa ABVIIa is an annex fund to ABVII Abingworth Bioventures IV Abingworth Bioventures III Abingworth Bioventures IIa Abingworth Bioventures II Abingworth Bioventures Biotechnology Venture Fund
2.Abingworth - Investment Criteria   (78%):
Investment success Funds Abingworth has raised six funds dedicated to investment in life sciences: Biotechnology Venture Fund has made 23 venture investments, of which 18 went public and 4 were acquired. Abingworth Bioventures made 14 venture investments, of which 10 went public and 4 were acquired....
3.BioAdvance Ventures : News : Press Releases : September 23, 2004   (72%):
News BioAdvance Ventures Announces Closing of $26 Million Early Stage Life Sciences Fund BioAdvance and Quaker BioVentures Partner to Attract More National Life Sciences Investment to Philadelphia Region Philadelphia and Wayne, PA - September 23, 2004 - BioAdvance, the Biotechnology Greenhouse of So...
4.BioAdvance Ventures : News : Press Releases : December 13, 2004   (57%):
News Neotropix Attracts $10 Million Series A Round For Development of Novel Virotherapies to Treat Cancer MALVERN, Pa.--(BUSINESS WIRE)--Dec. 13, 2004-- VIMAC Milestone Medica, Quaker BioVentures, and The Aurora Funds Co-lead Investment in Pennsylvania-based Company Neotropix(TM), Inc., a company de...
5.GBS Venture Partners :: News and Events   (55%):
GBS BioVentures III [10 May 2005 15:06] GBS Venture Partners, Australia s leading life science specialist venture capital investor, this week completed the close of its GBS BioVentures III Fund, with $145 million. Geoff Brooke of GBS said We were delighted with the level of interest in the fund and ...
6.BioAdvance Ventures : News : Press Releases : November 22, 2004   (54%):
News Transport Pharmaceuticals Secures $27 Million in Venture Financing to Continue Development of Unique Drug Delivery Platform Carlyle Venture Partners and Quaker BioVentures co-lead Series D funding; Company's innovative oral herpes treatment ready for Phase III clinical trials Framingham, MA and...
7.Easton Capital Investment Group::Renovis, Inc.   (54%):
Renovis, Inc. Renovis (NASD:RNVS) is a biopharmaceutical company that discovers and develops drugs to address neurological conditions and neuroinflammatory disorders. The Company has several drug candidates in development, including Cerovive, a Phase III drug for acute ischemic stroke that is partne...
8.GBS Venture Partners :: News and Events   (53%):
NEWS Sunshine Heart Quarterly In... Pharmaxis Ltd Announces Glo... CogState Announces Restruct... CogState Signs Agreement to... Enrolment Commenced in Arid... Novasys Medical Announces N... ASX Announcement - Clinica... Bronchitol Cystic Fibrosis ... Cortical Pty Ltd Presents M... CogState Signs Ag...
9.InterWest Partners - Investing in Information Technology & Life Sciences   (49%):
InterWest News InterWest Releases Portfolio News Portfolio Releases Events Portfolio Releases [ Portfolio Releases - Main ] Applied Spine Technologies Completes $15 Million Series B Round of Financing New investors include InterWest Partners and De Novo Ventures, joining Series A investors Oxford Bi...
10.BioAdvance Ventures : Advisory Board   (48%):
Advisory Board BioAdvance Ventures will have access through Quaker BioVentures and through the Biotechnology Greenhouse of Southeastern Pennsylvania to several leading biotech executives and academic advisors. For more on information about our affiliates see ( www.quakerbio.com ) and ( www.bioadvanc...
11.Venture capital alliances - syndicate firms from ARCH Venture Partners   (45%):
ARCH works with many other venture capital firms and institutional investors who serve as limited partners, co-investors, and sources of feedback for new company ideas. The following is a partial list of companies that have co-invested in ARCH portfolio companies as part of a syndicate. 3M Corporati...
12.BioAdvance Ventures : News : Press Releases : April 22, 2005   (45%):
News TargetRx Announces $15 Million in Funding Led By Quaker BioVentures Pharmaceutical Marketing Information Company Continues Momentum Horsham, PA - April 22, 2005 - TargetRx, a marketing information services company that assists pharmaceutical companies in effectively selling and marketing their ...
13.http://www.lillyventures.com/html/MTVportfolio.htm   (45%):
*** Replace left1.gif through left7.gif with the appropriate left-side image components e.Lilly Venture Fund Portfolio | Lilly BioVenture Fund Portfolio | Lilly MedTech Venture Fund Portfolio Remon Medical Technologies Inc , Waltham, MA and Caesaria, Israel Remon Medical Technologies develops and c...
14.Acorda :: Current Investors   (44%):
Acorda Therapeutics is a privately held biotechnology company devoted to developing therapies for individuals with spinal cord injury, multiple sclerosis, and related disorders of the nervous system. Since its inception in 1995, Acorda has raised over $140 million through a combination of individua...
15.Bioventures Management   (42%):
Peter Feinstein, General Partner Mr. Feinstein co-founded BioVentures Investors with Marc Goldberg and has been a General Partner since the inception of Fund I in 1999. In 1987, he founded Feinstein Kean Healthcare in Cambridge, MA, providing consulting and communications services to the biotechnol...
16.BioAdvance Ventures   (40%):
BioAdvance Ventures is an innovative new venture fund formed to invest in seed and early stage life science companies, located primarily in Southeastern Pennsylvania. The fund is sponsored by BioAdvance, the Biotechnology Greenhouse Corporation of Southeastern Pennsylvania and is managed by Quaker B...
17.BioAdvance Ventures   (40%):
BioAdvance Ventures is an innovative new venture fund formed to invest in seed and early stage life science companies, located primarily in Southeastern Pennsylvania. The fund is sponsored by BioAdvance, the Biotechnology Greenhouse Corporation of Southeastern Pennsylvania and is managed by Quaker B...
18.GBS Venture Partners :: News and Events   (40%):
NEWS Sunshine Heart Quarterly In... Pharmaxis Ltd Announces Glo... CogState Announces Restruct... CogState Signs Agreement to... Enrolment Commenced in Arid... Novasys Medical Announces N... ASX Announcement - Clinica... Bronchitol Cystic Fibrosis ... Cortical Pty Ltd Presents M... CogState Signs Ag...
19.Abingworth - Portfolio Companies   (39%):
Portfolio Companies Abingworth Bioventures IV Ablynx (Ghent, Belgium) is discovering and developing novel, proprietary antibody-like molecules called nanobodies. These nanobodies are being developed both as target validation tools and as therapeutics. The unique properties of nanobodies allow them t...
20.GBS Venture Partners :: News and Events   (39%):
Phenomix Closes Series B Financing at $40 Million [24 May 2005 16:38] San Diego, CA Phenomix Corporation, a drug discovery and development company, announced today the closing of a $40 million private placement of its Series B preferred stock, bringing the total amount raised since inception to $65....

Page: 1   2   3   4   5   6   7   8   9   10   11   12   13   14   15   16   17   18   19   20  

VC Directory: A   B   C   D   E   F   G   H   I   J   K   L   M   N   O   P   Q   R   S   T   U   V   W   X   Y   Z   Others